JP6616057B2 - ヒストンアセチル基転移酵素モジュレーターおよびその使用 - Google Patents
ヒストンアセチル基転移酵素モジュレーターおよびその使用 Download PDFInfo
- Publication number
- JP6616057B2 JP6616057B2 JP2013546423A JP2013546423A JP6616057B2 JP 6616057 B2 JP6616057 B2 JP 6616057B2 JP 2013546423 A JP2013546423 A JP 2013546423A JP 2013546423 A JP2013546423 A JP 2013546423A JP 6616057 B2 JP6616057 B2 JP 6616057B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- body weight
- disease
- incorporated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000003893 Histone acetyltransferases Human genes 0.000 title description 154
- 108090000246 Histone acetyltransferases Proteins 0.000 title description 152
- 150000001875 compounds Chemical class 0.000 claims description 347
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 223
- 229910052739 hydrogen Inorganic materials 0.000 claims description 71
- 229910052736 halogen Inorganic materials 0.000 claims description 49
- 150000002367 halogens Chemical class 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 39
- 239000001257 hydrogen Substances 0.000 claims description 35
- 150000002431 hydrogen Chemical class 0.000 claims description 29
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 16
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 3
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims 3
- 230000037396 body weight Effects 0.000 description 218
- 208000024827 Alzheimer disease Diseases 0.000 description 64
- -1 ethoxyl Chemical group 0.000 description 56
- 108010033040 Histones Proteins 0.000 description 55
- 238000000034 method Methods 0.000 description 53
- 239000000203 mixture Substances 0.000 description 53
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 51
- 230000006195 histone acetylation Effects 0.000 description 49
- 230000015654 memory Effects 0.000 description 49
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 45
- 241000699670 Mus sp. Species 0.000 description 45
- 230000000694 effects Effects 0.000 description 45
- 230000014509 gene expression Effects 0.000 description 43
- 108010040163 CREB-Binding Protein Proteins 0.000 description 41
- 102100021975 CREB-binding protein Human genes 0.000 description 39
- 239000000243 solution Substances 0.000 description 38
- 238000012360 testing method Methods 0.000 description 37
- 102000006947 Histones Human genes 0.000 description 34
- 108090000623 proteins and genes Proteins 0.000 description 34
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 32
- 102000003964 Histone deacetylase Human genes 0.000 description 32
- 108090000353 Histone deacetylase Proteins 0.000 description 32
- 230000021736 acetylation Effects 0.000 description 32
- 230000004770 neurodegeneration Effects 0.000 description 32
- 208000015122 neurodegenerative disease Diseases 0.000 description 32
- 238000006640 acetylation reaction Methods 0.000 description 31
- 230000027928 long-term synaptic potentiation Effects 0.000 description 31
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 30
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 28
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 25
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 25
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 25
- 102000012412 Presenilin-1 Human genes 0.000 description 25
- 108010036933 Presenilin-1 Proteins 0.000 description 25
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 24
- 239000012190 activator Substances 0.000 description 24
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 23
- 239000012044 organic layer Substances 0.000 description 23
- 239000011734 sodium Substances 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 201000011240 Frontotemporal dementia Diseases 0.000 description 21
- 230000008499 blood brain barrier function Effects 0.000 description 21
- 210000001218 blood-brain barrier Anatomy 0.000 description 21
- 125000001188 haloalkyl group Chemical group 0.000 description 21
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 21
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 20
- 238000003556 assay Methods 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 20
- 229910052757 nitrogen Inorganic materials 0.000 description 20
- 238000011282 treatment Methods 0.000 description 20
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 19
- 208000018737 Parkinson disease Diseases 0.000 description 19
- 230000004048 modification Effects 0.000 description 19
- 238000012986 modification Methods 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 19
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
- 208000023105 Huntington disease Diseases 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 239000003814 drug Substances 0.000 description 18
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 17
- 125000003118 aryl group Chemical group 0.000 description 17
- 238000003818 flash chromatography Methods 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- 230000003956 synaptic plasticity Effects 0.000 description 17
- 102100022846 Histone acetyltransferase KAT2B Human genes 0.000 description 16
- 229940079593 drug Drugs 0.000 description 16
- 101001047006 Homo sapiens Histone acetyltransferase KAT2B Proteins 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 102100040347 TAR DNA-binding protein 43 Human genes 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 229910052799 carbon Inorganic materials 0.000 description 15
- 230000001965 increasing effect Effects 0.000 description 15
- 230000013016 learning Effects 0.000 description 15
- 102000013498 tau Proteins Human genes 0.000 description 15
- 108010026424 tau Proteins Proteins 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 15
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 14
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 14
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 14
- 101000891092 Homo sapiens TAR DNA-binding protein 43 Proteins 0.000 description 14
- 230000015572 biosynthetic process Effects 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 208000010877 cognitive disease Diseases 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000007787 long-term memory Effects 0.000 description 13
- 238000010172 mouse model Methods 0.000 description 13
- 210000002569 neuron Anatomy 0.000 description 13
- 239000000047 product Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 208000011580 syndromic disease Diseases 0.000 description 13
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 12
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 12
- 108010077544 Chromatin Proteins 0.000 description 12
- 210000003483 chromatin Anatomy 0.000 description 12
- 230000007850 degeneration Effects 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 11
- 102000003802 alpha-Synuclein Human genes 0.000 description 11
- 108090000185 alpha-Synuclein Proteins 0.000 description 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 11
- VVWRJUBEIPHGQF-MDZDMXLPSA-N propan-2-yl (ne)-n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)\N=N\C(=O)OC(C)C VVWRJUBEIPHGQF-MDZDMXLPSA-N 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 206010008025 Cerebellar ataxia Diseases 0.000 description 10
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 10
- 101000882390 Homo sapiens Histone acetyltransferase p300 Proteins 0.000 description 10
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 10
- 208000021386 Sjogren Syndrome Diseases 0.000 description 10
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 10
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 10
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 10
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 10
- 230000026731 phosphorylation Effects 0.000 description 10
- 238000006366 phosphorylation reaction Methods 0.000 description 10
- 230000008569 process Effects 0.000 description 10
- 238000000746 purification Methods 0.000 description 10
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 9
- ASPDJZINBYYZRU-UHFFFAOYSA-N 5-amino-2-chlorobenzotrifluoride Chemical compound NC1=CC=C(Cl)C(C(F)(F)F)=C1 ASPDJZINBYYZRU-UHFFFAOYSA-N 0.000 description 9
- 102100024643 ATP-binding cassette sub-family D member 1 Human genes 0.000 description 9
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 9
- 101100477411 Dictyostelium discoideum set1 gene Proteins 0.000 description 9
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 101710103773 Histone H2B Proteins 0.000 description 9
- 102100021639 Histone H2B type 1-K Human genes 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 9
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 230000007246 mechanism Effects 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 210000000225 synapse Anatomy 0.000 description 9
- 102100021467 Histone acetyltransferase type B catalytic subunit Human genes 0.000 description 8
- 101001046967 Homo sapiens Histone acetyltransferase KAT2A Proteins 0.000 description 8
- 101000898976 Homo sapiens Histone acetyltransferase type B catalytic subunit Proteins 0.000 description 8
- 208000009829 Lewy Body Disease Diseases 0.000 description 8
- 201000002832 Lewy body dementia Diseases 0.000 description 8
- 206010039491 Sarcoma Diseases 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000003750 conditioning effect Effects 0.000 description 8
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 208000035475 disorder Diseases 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 210000001320 hippocampus Anatomy 0.000 description 8
- 239000003112 inhibitor Substances 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 8
- 230000035699 permeability Effects 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 230000003976 synaptic dysfunction Effects 0.000 description 8
- 238000003786 synthesis reaction Methods 0.000 description 8
- 206010003591 Ataxia Diseases 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 7
- 101000978776 Mus musculus Neurogenic locus notch homolog protein 1 Proteins 0.000 description 7
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 7
- 125000003368 amide group Chemical group 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 206010027175 memory impairment Diseases 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- 208000037259 Amyloid Plaque Diseases 0.000 description 6
- 201000003076 Angiosarcoma Diseases 0.000 description 6
- OYBMVMAXKOGYDC-UHFFFAOYSA-N CTPB Chemical compound CCCCCCCCCCCCCCCC1=CC=CC(OCC)=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 OYBMVMAXKOGYDC-UHFFFAOYSA-N 0.000 description 6
- 208000028698 Cognitive impairment Diseases 0.000 description 6
- 208000001258 Hemangiosarcoma Diseases 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 206010044221 Toxic encephalopathy Diseases 0.000 description 6
- 238000009825 accumulation Methods 0.000 description 6
- 230000035508 accumulation Effects 0.000 description 6
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 6
- 208000009956 adenocarcinoma Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000003542 behavioural effect Effects 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- 230000001149 cognitive effect Effects 0.000 description 6
- 230000007812 deficiency Effects 0.000 description 6
- 125000005843 halogen group Chemical group 0.000 description 6
- 238000003119 immunoblot Methods 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- 201000010901 lateral sclerosis Diseases 0.000 description 6
- 208000005264 motor neuron disease Diseases 0.000 description 6
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 210000000278 spinal cord Anatomy 0.000 description 6
- 208000002320 spinal muscular atrophy Diseases 0.000 description 6
- 230000000946 synaptic effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 206010065040 AIDS dementia complex Diseases 0.000 description 5
- 208000007848 Alcoholism Diseases 0.000 description 5
- 208000011403 Alexander disease Diseases 0.000 description 5
- 208000023434 Alpers-Huttenlocher syndrome Diseases 0.000 description 5
- 102000007371 Ataxin-3 Human genes 0.000 description 5
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 5
- 208000022526 Canavan disease Diseases 0.000 description 5
- 108091006146 Channels Proteins 0.000 description 5
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 5
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 5
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 5
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 5
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 description 5
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 208000027747 Kennedy disease Diseases 0.000 description 5
- 208000028226 Krabbe disease Diseases 0.000 description 5
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 5
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 description 5
- 208000014060 Niemann-Pick disease Diseases 0.000 description 5
- 208000031845 Pernicious anaemia Diseases 0.000 description 5
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 5
- 208000006289 Rett Syndrome Diseases 0.000 description 5
- 208000021811 Sandhoff disease Diseases 0.000 description 5
- 208000021235 Schilder disease Diseases 0.000 description 5
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 5
- 229910000831 Steel Inorganic materials 0.000 description 5
- 206010043189 Telangiectasia Diseases 0.000 description 5
- 231100000076 Toxic encephalopathy Toxicity 0.000 description 5
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 5
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 5
- SRHQOQMNBVOXCF-UHFFFAOYSA-N [4-chloro-3-(trifluoromethyl)phenyl]methanamine Chemical compound NCC1=CC=C(Cl)C(C(F)(F)F)=C1 SRHQOQMNBVOXCF-UHFFFAOYSA-N 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 201000007930 alcohol dependence Diseases 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 229960003920 cocaine Drugs 0.000 description 5
- 239000012043 crude product Substances 0.000 description 5
- 210000005154 hemibrain Anatomy 0.000 description 5
- 201000005202 lung cancer Diseases 0.000 description 5
- 208000020816 lung neoplasm Diseases 0.000 description 5
- 230000011987 methylation Effects 0.000 description 5
- 238000007069 methylation reaction Methods 0.000 description 5
- 201000011540 mitochondrial DNA depletion syndrome 4a Diseases 0.000 description 5
- 201000006417 multiple sclerosis Diseases 0.000 description 5
- 201000003631 narcolepsy Diseases 0.000 description 5
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 5
- 239000010959 steel Substances 0.000 description 5
- 208000009056 telangiectasis Diseases 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 4
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102000014461 Ataxins Human genes 0.000 description 4
- 108010078286 Ataxins Proteins 0.000 description 4
- 230000007082 Aβ accumulation Effects 0.000 description 4
- 206010004146 Basal cell carcinoma Diseases 0.000 description 4
- 206010005003 Bladder cancer Diseases 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 125000006414 CCl Chemical group ClC* 0.000 description 4
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 description 4
- 206010008342 Cervix carcinoma Diseases 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 4
- 238000008157 ELISA kit Methods 0.000 description 4
- 206010016717 Fistula Diseases 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 102100022893 Histone acetyltransferase KAT5 Human genes 0.000 description 4
- 208000016604 Lyme disease Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 208000026139 Memory disease Diseases 0.000 description 4
- 238000012347 Morris Water Maze Methods 0.000 description 4
- 206010052057 Neuroborreliosis Diseases 0.000 description 4
- 206010033128 Ovarian cancer Diseases 0.000 description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 102000012419 Presenilin-2 Human genes 0.000 description 4
- 108010036908 Presenilin-2 Proteins 0.000 description 4
- 102000029797 Prion Human genes 0.000 description 4
- 108091000054 Prion Proteins 0.000 description 4
- 208000024777 Prion disease Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 208000005587 Refsum Disease Diseases 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 4
- 208000002495 Uterine Neoplasms Diseases 0.000 description 4
- 208000030597 adult Refsum disease Diseases 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 4
- 210000004227 basal ganglia Anatomy 0.000 description 4
- 125000002619 bicyclic group Chemical group 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 201000010881 cervical cancer Diseases 0.000 description 4
- 230000019771 cognition Effects 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000012230 colorless oil Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 230000001054 cortical effect Effects 0.000 description 4
- 238000003381 deacetylation reaction Methods 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000003511 endothelial effect Effects 0.000 description 4
- 230000035612 epigenetic expression Effects 0.000 description 4
- 201000006061 fatal familial insomnia Diseases 0.000 description 4
- 230000003890 fistula Effects 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000030279 gene silencing Effects 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 230000006197 histone deacetylation Effects 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- PXZQEOJJUGGUIB-UHFFFAOYSA-N isoindolin-1-one Chemical compound C1=CC=C2C(=O)NCC2=C1 PXZQEOJJUGGUIB-UHFFFAOYSA-N 0.000 description 4
- VDBNYAPERZTOOF-UHFFFAOYSA-N isoquinolin-1(2H)-one Chemical compound C1=CC=C2C(=O)NC=CC2=C1 VDBNYAPERZTOOF-UHFFFAOYSA-N 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 208000014018 liver neoplasm Diseases 0.000 description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 231100000682 maximum tolerated dose Toxicity 0.000 description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 4
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- 201000008968 osteosarcoma Diseases 0.000 description 4
- 201000002528 pancreatic cancer Diseases 0.000 description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 206010041823 squamous cell carcinoma Diseases 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 201000003120 testicular cancer Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 206010046766 uterine cancer Diseases 0.000 description 4
- GZMNAKVQBLMPOE-UHFFFAOYSA-N 2-[[4-chloro-3-(trifluoromethyl)anilino]methyl]-3-ethoxyphenol Chemical compound CCOC1=CC=CC(O)=C1CNC1=CC=C(Cl)C(C(F)(F)F)=C1 GZMNAKVQBLMPOE-UHFFFAOYSA-N 0.000 description 3
- WQMAANNAZKNUDL-UHFFFAOYSA-N 2-dimethylaminoethyl chloride Chemical compound CN(C)CCCl WQMAANNAZKNUDL-UHFFFAOYSA-N 0.000 description 3
- 230000035495 ADMET Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000000044 Amnesia Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000009030 Carcinoma Diseases 0.000 description 3
- 102000014914 Carrier Proteins Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 102100039869 Histone H2B type F-S Human genes 0.000 description 3
- 101710116149 Histone acetyltransferase KAT5 Proteins 0.000 description 3
- 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 3
- 238000006751 Mitsunobu reaction Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 108010047956 Nucleosomes Proteins 0.000 description 3
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 206010060862 Prostate cancer Diseases 0.000 description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 3
- 239000012083 RIPA buffer Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000010535 acyclic diene metathesis reaction Methods 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000002583 anti-histone Effects 0.000 description 3
- 238000009227 behaviour therapy Methods 0.000 description 3
- 108091008324 binding proteins Proteins 0.000 description 3
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 230000007665 chronic toxicity Effects 0.000 description 3
- 231100000160 chronic toxicity Toxicity 0.000 description 3
- 230000003081 coactivator Effects 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 230000006196 deacetylation Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000007608 epigenetic mechanism Effects 0.000 description 3
- 230000004049 epigenetic modification Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 238000012226 gene silencing method Methods 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000007074 memory dysfunction Effects 0.000 description 3
- 208000025189 neoplasm of testis Diseases 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 210000001623 nucleosome Anatomy 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 125000001424 substituent group Chemical group 0.000 description 3
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 230000034512 ubiquitination Effects 0.000 description 3
- 238000010798 ubiquitination Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- FYMBVLZKCHZOCL-UHFFFAOYSA-N 2-ethoxy-6-hydroxybenzoic acid Chemical compound CCOC1=CC=CC(O)=C1C(O)=O FYMBVLZKCHZOCL-UHFFFAOYSA-N 0.000 description 2
- WOJKBHBBJMHDNJ-UHFFFAOYSA-N 8-hydroxy-3,4-dihydroisochromen-1-one Chemical compound C1COC(=O)C2=C1C=CC=C2O WOJKBHBBJMHDNJ-UHFFFAOYSA-N 0.000 description 2
- 230000005730 ADP ribosylation Effects 0.000 description 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001956 Amnestic symptoms Diseases 0.000 description 2
- 206010003571 Astrocytoma Diseases 0.000 description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 2
- 208000003950 B-cell lymphoma Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 101100026251 Caenorhabditis elegans atf-2 gene Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000005243 Chondrosarcoma Diseases 0.000 description 2
- 201000009047 Chordoma Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000009798 Craniopharyngioma Diseases 0.000 description 2
- 230000007067 DNA methylation Effects 0.000 description 2
- 206010012289 Dementia Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010014967 Ependymoma Diseases 0.000 description 2
- 208000006168 Ewing Sarcoma Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100033071 Histone acetyltransferase KAT6A Human genes 0.000 description 2
- 102100039999 Histone deacetylase 2 Human genes 0.000 description 2
- 208000017604 Hodgkin disease Diseases 0.000 description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000944179 Homo sapiens Histone acetyltransferase KAT6A Proteins 0.000 description 2
- 101001035011 Homo sapiens Histone deacetylase 2 Proteins 0.000 description 2
- 101000602930 Homo sapiens Nuclear receptor coactivator 2 Proteins 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 208000018142 Leiomyosarcoma Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 208000000172 Medulloblastoma Diseases 0.000 description 2
- 208000036626 Mental retardation Diseases 0.000 description 2
- 206010027406 Mesothelioma Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 101000654471 Mus musculus NAD-dependent protein deacetylase sirtuin-1 Proteins 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- HRNLUBSXIHFDHP-UHFFFAOYSA-N N-(2-aminophenyl)-4-[[[4-(3-pyridinyl)-2-pyrimidinyl]amino]methyl]benzamide Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC1=NC=CC(C=2C=NC=CC=2)=N1 HRNLUBSXIHFDHP-UHFFFAOYSA-N 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010029260 Neuroblastoma Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 102000011244 Nuclear receptor coactivator Human genes 0.000 description 2
- 108050001461 Nuclear receptor coactivator Proteins 0.000 description 2
- 102100037226 Nuclear receptor coactivator 2 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 201000010133 Oligodendroglioma Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 2
- 206010038389 Renal cancer Diseases 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- 201000000582 Retinoblastoma Diseases 0.000 description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 2
- 108050002485 Sirtuin Proteins 0.000 description 2
- 102000011990 Sirtuin Human genes 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 101150036909 TAF1 gene Proteins 0.000 description 2
- 101710150875 TAR DNA-binding protein 43 Proteins 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 208000014070 Vestibular schwannoma Diseases 0.000 description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- JOSCNYCOYXTLTN-GFCCVEGCSA-N [3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxyphenyl]-[(3R)-3-(hydroxymethyl)pyrrolidin-1-yl]methanone Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C=CC=1)C(=O)N1C[C@@H](CC1)CO JOSCNYCOYXTLTN-GFCCVEGCSA-N 0.000 description 2
- 102000005421 acetyltransferase Human genes 0.000 description 2
- 108020002494 acetyltransferase Proteins 0.000 description 2
- 208000004064 acoustic neuroma Diseases 0.000 description 2
- 108091006088 activator proteins Proteins 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 description 2
- 229960003094 belinostat Drugs 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 208000029028 brain injury Diseases 0.000 description 2
- 208000003362 bronchogenic carcinoma Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 208000006990 cholangiocarcinoma Diseases 0.000 description 2
- 239000000544 cholinesterase inhibitor Substances 0.000 description 2
- 230000002759 chromosomal effect Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 2
- 230000006329 citrullination Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940125898 compound 5 Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 2
- 208000002445 cystadenocarcinoma Diseases 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 239000002612 dispersion medium Substances 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000003596 drug target Substances 0.000 description 2
- 230000008406 drug-drug interaction Effects 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- 201000002222 hemangioblastoma Diseases 0.000 description 2
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 2
- 210000004295 hippocampal neuron Anatomy 0.000 description 2
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 201000008319 inclusion body myositis Diseases 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 229940102223 injectable solution Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- SANOUVWGPVYVAV-UHFFFAOYSA-N isovaleramide Chemical compound CC(C)CC(N)=O SANOUVWGPVYVAV-UHFFFAOYSA-N 0.000 description 2
- 201000010982 kidney cancer Diseases 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 206010027191 meningioma Diseases 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 229960001047 methyl salicylate Drugs 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 208000001611 myxosarcoma Diseases 0.000 description 2
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
- TZHLDFAKTWDTOW-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(dimethylamino)ethoxy]-6-ethoxybenzamide Chemical compound CCOC1=CC=CC(OCCN(C)C)=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 TZHLDFAKTWDTOW-UHFFFAOYSA-N 0.000 description 2
- IMPCDRMQCCZGBV-UHFFFAOYSA-N n-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-2-ethoxy-6-hydroxybenzamide Chemical compound CCOC1=CC=CC(O)=C1C(=O)NCC1=CC=C(Cl)C(C(F)(F)F)=C1 IMPCDRMQCCZGBV-UHFFFAOYSA-N 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 230000007171 neuropathology Effects 0.000 description 2
- 230000000324 neuroprotective effect Effects 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000008599 nitrosative stress Effects 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 238000012346 open field test Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 108010006198 p300-CBP-associated factor Proteins 0.000 description 2
- 208000004019 papillary adenocarcinoma Diseases 0.000 description 2
- 201000010198 papillary carcinoma Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 238000009521 phase II clinical trial Methods 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical class C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000001144 postural effect Effects 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 2
- 201000008407 sebaceous adenocarcinoma Diseases 0.000 description 2
- 201000007321 sebaceous carcinoma Diseases 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000003107 substituted aryl group Chemical group 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000010741 sumoylation Effects 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 201000010965 sweat gland carcinoma Diseases 0.000 description 2
- 230000003977 synaptic function Effects 0.000 description 2
- 229960001685 tacrine Drugs 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- 208000008732 thymoma Diseases 0.000 description 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 2
- 229960000237 vorinostat Drugs 0.000 description 2
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- QLPXHECKUSZTMH-GSVOUGTGSA-N (2r)-2-amino-3-methyl-3-nitrososulfanylbutanoic acid Chemical compound O=NSC(C)(C)[C@H](N)C(O)=O QLPXHECKUSZTMH-GSVOUGTGSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 description 1
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- YBZAVRDNSPUMFK-UHFFFAOYSA-N 2, 6-Dihydroxy-4-methylbenzoic acid, Natural products CC1=CC(O)=C(C(O)=O)C(O)=C1 YBZAVRDNSPUMFK-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- CQZIWRAHPSIFMC-UHFFFAOYSA-N 2-[2-[[4-chloro-3-(trifluoromethyl)phenyl]iminomethyl]-3-ethoxyphenoxy]-n,n-dimethylethanamine Chemical compound CCOC1=CC=CC(OCCN(C)C)=C1C=NC1=CC=C(Cl)C(C(F)(F)F)=C1 CQZIWRAHPSIFMC-UHFFFAOYSA-N 0.000 description 1
- XETZWJJCOIELNR-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-4-[2-(dimethylamino)ethoxy]isoindole-1,3-dione Chemical compound O=C1C=2C(OCCN(C)C)=CC=CC=2C(=O)N1C1=CC=C(Cl)C(C(F)(F)F)=C1 XETZWJJCOIELNR-UHFFFAOYSA-N 0.000 description 1
- JDYOEIIUYWSTOL-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-4-ethoxyisoindole-1,3-dione Chemical compound O=C1C=2C(OCC)=CC=CC=2C(=O)N1C1=CC=C(Cl)C(C(F)(F)F)=C1 JDYOEIIUYWSTOL-UHFFFAOYSA-N 0.000 description 1
- XGQZTRMLFSCQMK-UHFFFAOYSA-N 2-[4-chloro-3-(trifluoromethyl)phenyl]-4-hydroxyisoindole-1,3-dione Chemical compound O=C1C=2C(O)=CC=CC=2C(=O)N1C1=CC=C(Cl)C(C(F)(F)F)=C1 XGQZTRMLFSCQMK-UHFFFAOYSA-N 0.000 description 1
- GPTMFTAOXBHXEL-UHFFFAOYSA-N 2-amino-6-ethoxybenzoic acid Chemical compound CCOC1=CC=CC(N)=C1C(O)=O GPTMFTAOXBHXEL-UHFFFAOYSA-N 0.000 description 1
- 125000003635 2-dimethylaminoethoxy group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])O* 0.000 description 1
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 description 1
- WFCSWCVEJLETKA-UHFFFAOYSA-N 2-piperazin-1-ylethanol Chemical compound OCCN1CCNCC1 WFCSWCVEJLETKA-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical class C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- HWFLKVWNEHWTST-UHFFFAOYSA-N 3-[4-chloro-3-(trifluoromethyl)phenyl]-5-ethoxy-2,4-dihydro-1,3-benzoxazine Chemical compound C1C=2C(OCC)=CC=CC=2OCN1C1=CC=C(Cl)C(C(F)(F)F)=C1 HWFLKVWNEHWTST-UHFFFAOYSA-N 0.000 description 1
- ACZGCWSMSTYWDQ-UHFFFAOYSA-N 3h-1-benzofuran-2-one Chemical class C1=CC=C2OC(=O)CC2=C1 ACZGCWSMSTYWDQ-UHFFFAOYSA-N 0.000 description 1
- ZAPMTSHEXFEPSD-UHFFFAOYSA-N 4-(2-chloroethyl)morpholine Chemical compound ClCCN1CCOCC1 ZAPMTSHEXFEPSD-UHFFFAOYSA-N 0.000 description 1
- GQBONCZDJQXPLV-UHFFFAOYSA-N 4-aminoisoindole-1,3-dione Chemical class NC1=CC=CC2=C1C(=O)NC2=O GQBONCZDJQXPLV-UHFFFAOYSA-N 0.000 description 1
- OBKXEAXTFZPCHS-UHFFFAOYSA-N 4-phenylbutyric acid Chemical compound OC(=O)CCCC1=CC=CC=C1 OBKXEAXTFZPCHS-UHFFFAOYSA-N 0.000 description 1
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical class C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
- 102000057234 Acyl transferases Human genes 0.000 description 1
- 108700016155 Acyl transferases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 1
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical group NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000020925 Bipolar disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100123577 Caenorhabditis elegans hda-1 gene Proteins 0.000 description 1
- 101100042630 Caenorhabditis elegans sin-3 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000013392 Carboxylesterase Human genes 0.000 description 1
- 108010051152 Carboxylesterase Proteins 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 102100032616 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 229940122041 Cholinesterase inhibitor Drugs 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 101100411591 Dictyostelium discoideum rab8B gene Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101100098711 Drosophila melanogaster Taf1 gene Proteins 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101150046226 ELP3 gene Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 102100035074 Elongator complex protein 3 Human genes 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000041143 GNAT family Human genes 0.000 description 1
- 108091061015 GNAT family Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108091005772 HDAC11 Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010019851 Hepatotoxicity Diseases 0.000 description 1
- 108010034791 Heterochromatin Proteins 0.000 description 1
- 102100033070 Histone acetyltransferase KAT6B Human genes 0.000 description 1
- 102100033068 Histone acetyltransferase KAT7 Human genes 0.000 description 1
- 102100033069 Histone acetyltransferase KAT8 Human genes 0.000 description 1
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 102100038715 Histone deacetylase 8 Human genes 0.000 description 1
- 101000877382 Homo sapiens Elongator complex protein 3 Proteins 0.000 description 1
- 101000828609 Homo sapiens Flotillin-2 Proteins 0.000 description 1
- 101001051083 Homo sapiens Galectin-12 Proteins 0.000 description 1
- 101001034009 Homo sapiens Glutamate receptor-interacting protein 1 Proteins 0.000 description 1
- 101001046996 Homo sapiens Histone acetyltransferase KAT5 Proteins 0.000 description 1
- 101000944166 Homo sapiens Histone acetyltransferase KAT7 Proteins 0.000 description 1
- 101000944170 Homo sapiens Histone acetyltransferase KAT8 Proteins 0.000 description 1
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 1
- 101001032118 Homo sapiens Histone deacetylase 8 Proteins 0.000 description 1
- 101100019690 Homo sapiens KAT6B gene Proteins 0.000 description 1
- 101000602926 Homo sapiens Nuclear receptor coactivator 1 Proteins 0.000 description 1
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 description 1
- 101000651467 Homo sapiens Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102100024022 Inactive heparanase-2 Human genes 0.000 description 1
- 101710133360 Inactive heparanase-2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 108010068261 Mi-2 Nucleosome Remodeling and Deacetylase Complex Proteins 0.000 description 1
- 102000002499 Mi-2 Nucleosome Remodeling and Deacetylase Complex Human genes 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- MHJGBZGIAZOUHO-UHFFFAOYSA-N N-(3-methylbutoxy)benzamide Chemical compound C(C1=CC=CC=C1)(=O)NOCCC(C)C MHJGBZGIAZOUHO-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- YALNUENQHAQXEA-UHFFFAOYSA-N N-[4-[(hydroxyamino)-oxomethyl]phenyl]carbamic acid [6-(diethylaminomethyl)-2-naphthalenyl]methyl ester Chemical compound C1=CC2=CC(CN(CC)CC)=CC=C2C=C1COC(=O)NC1=CC=C(C(=O)NO)C=C1 YALNUENQHAQXEA-UHFFFAOYSA-N 0.000 description 1
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 101710112216 NAD-dependent histone deacetylase SIR2 Proteins 0.000 description 1
- ACFIXJIJDZMPPO-NNYOXOHSSA-N NADPH Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](OP(O)(O)=O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NNYOXOHSSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 208000007641 Pinealoma Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000015499 Presenilins Human genes 0.000 description 1
- 108010050254 Presenilins Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000025535 REM sleep behavior disease Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 101100148749 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAS2 gene Proteins 0.000 description 1
- 101100148751 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SAS3 gene Proteins 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010085012 Steroid Receptors Proteins 0.000 description 1
- 102000007451 Steroid Receptors Human genes 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007792 alzheimer disease pathology Effects 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 230000003941 amyloidogenesis Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940039856 aricept Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229910052789 astatine Inorganic materials 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 150000003936 benzamides Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037185 brain physiology Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000002230 centromere Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 208000030499 combat disease Diseases 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 210000003618 cortical neuron Anatomy 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000000850 deacetylating effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 210000003520 dendritic spine Anatomy 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 201000002246 embryonal cancer Diseases 0.000 description 1
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 description 1
- 229950005837 entinostat Drugs 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000010932 epithelial neoplasm Diseases 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- FXANKCVUGUNPBD-UHFFFAOYSA-N ethyl 4-ethoxy-2-hydroxybenzoate Chemical compound CCOC(=O)C1=CC=C(OCC)C=C1O FXANKCVUGUNPBD-UHFFFAOYSA-N 0.000 description 1
- BSRPONIXRNBZGU-UHFFFAOYSA-N ethyl 5-ethoxy-2-hydroxybenzoate Chemical compound CCOC(=O)C1=CC(OCC)=CC=C1O BSRPONIXRNBZGU-UHFFFAOYSA-N 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 229940108366 exelon Drugs 0.000 description 1
- 230000021824 exploration behavior Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000006390 fear memory Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 230000007686 hepatotoxicity Effects 0.000 description 1
- 210000004458 heterochromatin Anatomy 0.000 description 1
- 229940125697 hormonal agent Drugs 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000055128 human TARDBP Human genes 0.000 description 1
- 108091003098 human bone sialoprotein (35-62) Proteins 0.000 description 1
- 102000027012 human bone sialoprotein (35-62) Human genes 0.000 description 1
- ZUFVXZVXEJHHBN-UHFFFAOYSA-N hydron;1,2,3,4-tetrahydroacridin-9-amine;chloride Chemical compound [Cl-].C1=CC=C2C([NH3+])=C(CCCC3)C3=NC2=C1 ZUFVXZVXEJHHBN-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
- 208000025036 lymphosarcoma Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000005055 memory storage Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- LDMWSLGGVTVJPG-UHFFFAOYSA-N minaprine Chemical compound CC1=CC(C=2C=CC=CC=2)=NN=C1NCCN1CCOCC1 LDMWSLGGVTVJPG-UHFFFAOYSA-N 0.000 description 1
- 229960004758 minaprine Drugs 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 230000004973 motor coordination Effects 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- WJPPWIJLQGGBIT-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(diethylamino)ethoxy]-6-ethoxybenzamide Chemical compound CCOC1=CC=CC(OCCN(CC)CC)=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 WJPPWIJLQGGBIT-UHFFFAOYSA-N 0.000 description 1
- OQHZBOOMJGRPLJ-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(dimethylamino)ethoxy]-4-ethoxybenzamide Chemical compound CN(C)CCOC1=CC(OCC)=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 OQHZBOOMJGRPLJ-UHFFFAOYSA-N 0.000 description 1
- LMCQVUCQEBXYPI-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(dimethylamino)ethoxy]-5-ethoxybenzamide Chemical compound CCOC1=CC=C(OCCN(C)C)C(C(=O)NC=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 LMCQVUCQEBXYPI-UHFFFAOYSA-N 0.000 description 1
- ZZMFILITNGQXOS-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[2-(dimethylamino)ethoxy]benzamide Chemical compound CN(C)CCOC1=CC=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 ZZMFILITNGQXOS-UHFFFAOYSA-N 0.000 description 1
- UFJNHRPRQIFLQC-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(diethylamino)propoxy]-6-ethoxybenzamide Chemical compound CCOC1=CC=CC(OCCCN(CC)CC)=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 UFJNHRPRQIFLQC-UHFFFAOYSA-N 0.000 description 1
- QMPPUCLYDLSOOI-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-[3-(dimethylamino)propoxy]-6-ethoxybenzamide Chemical compound CCOC1=CC=CC(OCCCN(C)C)=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 QMPPUCLYDLSOOI-UHFFFAOYSA-N 0.000 description 1
- RIHVVSUFNWZMRF-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-[2-(4-methylpiperazin-1-yl)ethoxy]benzamide Chemical compound C=1C=C(Cl)C(C(F)(F)F)=CC=1NC(=O)C=1C(OCC)=CC=CC=1OCCN1CCN(C)CC1 RIHVVSUFNWZMRF-UHFFFAOYSA-N 0.000 description 1
- ZNXAGZVJJIZPLV-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-ethoxy-6-hydroxybenzamide Chemical compound CCOC1=CC=CC(O)=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 ZNXAGZVJJIZPLV-UHFFFAOYSA-N 0.000 description 1
- MXSJAPIEXXAEKO-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-hydroxybenzamide Chemical compound OC1=CC=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 MXSJAPIEXXAEKO-UHFFFAOYSA-N 0.000 description 1
- AQJBXYBDNZHZRE-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-2-propoxybenzamide Chemical compound CCCOC1=CC=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 AQJBXYBDNZHZRE-UHFFFAOYSA-N 0.000 description 1
- YUTQVTHJKHUIFO-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-4-ethoxy-2-hydroxybenzamide Chemical compound OC1=CC(OCC)=CC=C1C(=O)NC1=CC=C(Cl)C(C(F)(F)F)=C1 YUTQVTHJKHUIFO-UHFFFAOYSA-N 0.000 description 1
- FZILCZLBZBZJEF-UHFFFAOYSA-N n-[4-chloro-3-(trifluoromethyl)phenyl]-5-ethoxy-2-hydroxybenzamide Chemical compound CCOC1=CC=C(O)C(C(=O)NC=2C=C(C(Cl)=CC=2)C(F)(F)F)=C1 FZILCZLBZBZJEF-UHFFFAOYSA-N 0.000 description 1
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 1
- ITNSVLPKZNJFEA-UHFFFAOYSA-N n-[[4-chloro-3-(trifluoromethyl)phenyl]methyl]-2-[2-(dimethylamino)ethoxy]-6-ethoxybenzamide Chemical compound CCOC1=CC=CC(OCCN(C)C)=C1C(=O)NCC1=CC=C(Cl)C(C(F)(F)F)=C1 ITNSVLPKZNJFEA-UHFFFAOYSA-N 0.000 description 1
- RBAQOAYHTJXKRR-UHFFFAOYSA-N n-phenylpyridazin-3-amine Chemical compound C=1C=CN=NC=1NC1=CC=CC=C1 RBAQOAYHTJXKRR-UHFFFAOYSA-N 0.000 description 1
- 229940033872 namenda Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000009635 nitrosylation Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- FPOHNWQLNRZRFC-ZHACJKMWSA-N panobinostat Chemical compound CC=1NC2=CC=CC=C2C=1CCNCC1=CC=C(\C=C\C(=O)NO)C=C1 FPOHNWQLNRZRFC-ZHACJKMWSA-N 0.000 description 1
- 229960005184 panobinostat Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000002732 pharmacokinetic assay Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000024724 pineal body neoplasm Diseases 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- LJCNRYVRMXRIQR-OLXYHTOASA-L potassium sodium L-tartrate Chemical compound [Na+].[K+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O LJCNRYVRMXRIQR-OLXYHTOASA-L 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940051845 razadyne Drugs 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000014493 regulation of gene expression Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
- 229950005741 rolipram Drugs 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 230000006403 short-term memory Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011006 sodium potassium tartrate Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000007607 synaptic alteration Effects 0.000 description 1
- 201000008753 synovium neoplasm Diseases 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 102000055501 telomere Human genes 0.000 description 1
- 108091035539 telomere Proteins 0.000 description 1
- 210000003411 telomere Anatomy 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
- C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/54—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C217/56—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms
- C07C217/58—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/64—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
- C07C251/24—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having carbon atoms of imino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
- C07D265/12—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
- C07D265/14—1,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
Description
本発明は、国立神経疾患・脳卒中研究所(National Institute of Neurological Disorders and Stroke)(NINDS)によって授与された認可番号R01−NS049442号、国立衛生研究所(National Institute of Health)(NIH)によって授与された認可番号第PO1AG17490号、NIHによって授与された認可番号第U01AG031294号、NIHによって授与された認可番号第U01AG14351号のもとで、政府の支援を受けてなされた。政府は、本発明において特定の権利を有する。
Arは
RaはH、C1−C6−アルキル、C1−C6−ハロアルキル、O−(C1−C6−アルキル)、O−(C1−C6−ハロアルキル)、ハロゲン、CNまたはNO2であり;
RbはH、C1−C6−アルキル、C2−C6−アルケニル、C3−C8−シクロアルキル、C2−C6−ヘテロアルキル、C3−C8−ヘテロシクロアルキル、アリール、ヘテロアリール、O−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C2−C6−アルケニル)、O−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C1−C6−アルキル)、N(R10)−(C3−C8−シクロアルキル)、S−(C1−C6−アルキル)、O−(C2−C6−アルキル)−N(R10)2、O−(C3−C8−シクロアルキル)−N(R10)2、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、O−(C3−C8−シクロアルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、O−アリールまたは−O−ヘテロアリールであり;
RcはH、−(C1−C6−アルキル)、O−(C1−C6−アルキル)、C(=O)NH−フェニルであり、式中、フェニルは一つ以上のハロまたはハロアルキルで置換されており;
RdはH、OH、−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C3−C8−ヘテロシクロアルキル)、O−(C2−C6−アルケニル)、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、−N(R10)−(C1−C6−アルキル)、−N(R10)−(C2−C6−アルケニル)、−N(R10)−(C3−C8−シクロアルキル)、−N(R10)−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、S−(C2−C6−アルキル)−N(R10)2、OCH2C(O)O−アルキル、O−アリール、N−アリール、O−ヘテロアリール、またはN−ヘテロアリールであり;
WおよびZは互いに独立してNまたはCR1であり;
Xは−CO−、−CON(R10)−、−CON(R10)(CH2)n−、−(CH2)nCON(R10)−、−(CH2)nCON(R10)(CH2)n−、−SON(R10)−、−SON(R10)(CH2)n−、−SO2N(R10)−、−SO2N(R10)(CH2)n−、−N(R10)C(=O)N(R10)−、−N(R10)CO−、−N(R10)CO(CH2)n−、または−N(R10)CO(CH2)n−、−(CH2)nN(R10)−、−C=N−であり;または
ArおよびXは互いに結合して
R1はH、ハロゲン、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)N(R10)2であり;
R2はH、C1−C6−アルキル、C1−C6−ハロアルキル、O−(C1−C6−アルキル)、O−(C1−C6−ハロアルキル)、ハロゲン、CN、またはNO2であり;
R3はシクロアルキルアミノであり、N(R10)、OおよびSから選択されるヘテロ原子を含んでいてもよく;
R10は互いに独立してH、−(C1−C4−アルキル)、−(C1−C4−ハロアルキル)、−(C3−C8−シクロアルキル)、−(C3−C8−ヘテロシクロアルキル)、アリールまたはヘテロアリールであり;
nはそれぞれ互いに独立して1〜3の整数である化合物またはその薬剤的に許容される塩または水和物に関し;但し、Arは
YはCH、C−ハロゲンまたはC−CNであり;
RbはH、O−(C1−C2−アルキル)、S−(C1−C2−アルキル)、O−シクロペンチル、OCH2CH2N(CH3)2またはCH2CH2CH2N(CH3)2であり;
RcはH;C(=O)NH−フェニルであり、式中フェニルは一つ以上のハロまたはハロアルキルで置換されており;
RdはH、C1−C5−アルキル、OH、O−アルキル、OCH2CH2N(CH3)2、CH2CH2CH2N(CH3)2、SCH2CH2N(CH3)2またはOCH2C(=O)O−アルキルであり;
ZはCH、C−O−(C1−C2−アルキル)、C−OCH2CH2N(CH3)2であり;
XはCONH、SONH、SO2NH、NHC(=O)NHまたはNHCOであり、またはその薬剤的に許容される塩または水和物。
式中WはC−OCH2CH2N(CH3)2であり、ZはCHであり、Rbは水素であり、Rcは水素であり、Rdは水素であり;または
式中WおよびZはそれぞれCHであり、Rbはシクロペンチルオキシであり、Rcは水素であり、Rdは−OCH2CH2N(CH3)2であり;または
式中WおよびZはそれぞれCHであり、Rbは−OCH2CH2N(CH3)2であり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、Rdは−OCH2CH2N(CH3)2であり;または
式中WはCHであり、ZはC−エトキシであり、Rbはエトキシであり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、Rdは水素であり;または
式中WおよびZはそれぞれCHであり、Rbは−CH2CH2CH2N(CH3)2であり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、Rdは−CH2CH2CH2N(CH3)2または水素であり;または
式中WおよびZはそれぞれCHであり、Rbはエトキシであり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、Rdは水素または−OCH2CH2N(CH3)2であり;または
式中WおよびZは窒素であり、Rbはエトキシであり、Rcは水素であり、Rdは−OCH2CH2N(CH3)2であり;または
RaはH、ハロゲンまたはハロアルキルであり;
RbはH、O−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C2−C6−アルケニル)、O−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C1−C6−アルキル)、N(R10)−(C3−C8−シクロアルキル)、O−(C2−C6−アルキル)−N(R10)2、O−(C3−C8−シクロアルキル)−N(R10)2、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、O−(C3−C8−シクロアルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、O−アリール、またはO−ヘテロアリールであり;
RcはH、−(C1−C6−アルキル)またはO−(C1−C6−アルキル)であり;
RdはH、OH、C1−C6−アルキル、O−(C3−C8−シクロアルキル)、O−(C3−C8−ヘテロシクロアルキル)、O−(C1−C6−アルキル)、O−(C2−C6−アルケニル)、O−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、−N(R10)−(C1−C6−アルキル)、−N(R10)−(C3−C8−シクロアルキル)、−N(R10)−(C3−C8−ヘテロシクロアルキル)、−N(R10)−(C2−C6−アルケニル)、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、O−アリール、N−アリール、O−ヘテロアリールまたはN−ヘテロアリールであり;
WおよびZはCR1であり;
Xは−CO−、−CON(R10)−、−CON(R10)(CH2)n−、−(CH2)nN(R10)−、−C=N−であり;または
ArおよびXは互いに結合して
YはCR2であり;
R1はH、ハロゲン、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)N(R10)2であり;
R2はハロゲンまたはハロアルキルであり;
R3はシクロアルキルアミノであり、N(R10)、OおよびSから選択されるヘテロ原子を含んでいてもよく;
R10は互いに独立してH、−(C1−C4−アルキル)、−(C1−C4−ハロアルキル)、−(C3−C8−シクロアルキル)、−(C3−C8−ヘテロシクロアルキル)、アリールまたはヘテロアリールであり;
nは1〜3の整数であり、またはその薬剤的に許容される塩。
RbはH、C1−C6−アルキル、C2−C6−アルケニル、C3−C8−シクロアルキル、C2−C6−ヘテロアルキル、C3−C8−ヘテロシクロアルキル、アリール、ヘテロアリール、O−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C2−C6−アルケニル)、O−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C1−C6−アルキル)、N(R10)−(C3−C8−シクロアルキル)、S−(C1−C6−アルキル)、O−(C2−C6−アルキル)−N(R10)2、O−(C3−C8−シクロアルキル)−N(R10)2、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、O−(C3−C8−シクロアルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、O−アリール、またはO−ヘテロアリールであり、
RcはH、−(C1−C6−アルキル)、O−(C1−C6−アルキル)、C(=O)NH−フェニルであり、フェニルは1つ以上のハロまたはハロアルキルで置換され、
RdはH、OH、−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C3−C8−ヘテロシクロアルキル)、O−(C2−C6−アルケニル)、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、−N(R10)−(C1−C6−アルキル)、−N(R10)−(C2−C6−アルケニル)、−N(R10)−(C3−C8−シクロアルキル)、−N(R10)−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、S−(C2−C6−アルキル)−N(R10)2、OCH2C(O)O−アルキル、O−アリール、N−アリール、O−ヘテロアリール、またはN−ヘテロアリールであり、
WおよびZは独立してNまたはCR1であり、
Xは−CO−、−CON(R10)−、−CON(R10)(CH2)n−、−(CH2)nCON(R10)−、−(CH2)nCON(R10)(CH2)n−、−SON(R10)−、−SON(R10)(CH2)n−、−SO2N(R10)−、−SO2N(R10)(CH2)n−、−N(R10)C(=O)N(R10)−、−N(R10)CO−、−N(R10)CO(CH2)n−、または−N(R10)CO(CH2)n−、−(CH2)nN(R10)−、−C=N−であり、または
ArおよびXは一緒になって
YはNまたはCR2であり、
R1はH、ハロゲン、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)N(R10)2であり、
R2はH、C1−C6−アルキル、C1−C6−ハロアルキル、O−(C1−C6−アルキル)、O−(C1−C6−ハロアルキル)、ハロゲン、CN、またはNO2であり、
R3はシクロアルキルアミノであり、N(R10)、OおよびSから選択されるヘテロ原子を含んでもよく、
R10は独立してH、−(C1−C4−アルキル)、−(C1−C4−ハロアルキル)、−(C3−C8−シクロアルキル)、−(C3−C8−ヘテロシクロアルキル)、アリールまたはヘテロアリールであり、および
nはそれぞれ独立して1〜3の整数であり、または薬剤的に許容可能な塩またはその水和物であり、ただし、Arは以下の構造式ではない。
RbはH、C1−C6−アルキル、C2−C6−アルケニル、C3−C8−シクロアルキル、C2−C6−ヘテロアルキル、C3−C8−ヘテロシクロアルキル、アリール、ヘテロアリール、O−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C2−C6−アルケニル)、O−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C1−C6−アルキル)、N(R10)−(C3−C8−シクロアルキル)、S−(C1−C6−アルキル)、O−(C2−C6−アルキル)−N(R10)2、O−(C3−C8−シクロアルキル)−N(R10)2、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、O−(C3−C8−シクロアルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、O−アリール、またはO−ヘテロアリールであり、
RcはH、−(C1−C6−アルキル)、O−(C1−C6−アルキル)、C(=O)NH−フェニルであり、フェニルは1つ以上のハロまたはハロアルキルで置換され、
RdはH、OH、C1−C6−アルキル、O−(C3−C8−シクロアルキル)、O−(C3−C8−ヘテロシクロアルキル)、O−(C2−C6−アルケニル)、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、−N(R10)−(C1−C6−アルキル)、−N(R10)−(C2−C6−アルケニル)、−N(R10)−(C3−C8−シクロアルキル)、−N(R10)−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、S−(C2−C6−アルキル)−N(R10)2、OCH2C(O)O−アルキル、O−アリール、N−アリール、O−ヘテロアリール、またはN−ヘテロアリールであり、
WおよびZは独立してNまたはCR1であり、
Xは−CO−、−CON(R10)−、−CON(R10)(CH2)n−、−(CH2)nCON(R10)−、−(CH2)nCON(R10)(CH2)n−、−SON(R10)−、−SON(R10)(CH2)n−、−SO2N(R10)−、−SO2N(R10)(CH2)n−、−N(R10)C(=O)N(R10)−、−N(R10)CO−、−N(R10)CO(CH2)n−、または−N(R10)CO(CH2)n−、−(CH2)nN(R10)−、−C=N−であり、または
ArおよびXは一緒になって
YはNまたはCR2であり、
R1はH、ハロゲン、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)N(R10)2であり、
R2はH、ハロゲン、ハロアルキル、NO2、またはCNであり、
R3はシクロアルキルアミノであり、N(R10)、OおよびSから選択されるヘテロ原子を含んでもよく、
R10は独立してH、−(C1−C4−アルキル)、−(C1−C4−ハロアルキル)、−(C3−C8−シクロアルキル)、−(C3−C8−ヘテロシクロアルキル)、アリールまたはヘテロアリールであり、および
nは1〜3の整数であり、または薬剤的に許容可能な塩であり、ただし、Arは以下の構造式ではない。
YはCH、C−ハロゲン、またはC−CNであり、
RbはH、O−(C1−C2−アルキル)、S−(C1−C2−アルキル)、O−シクロペンチル、OCH2CH2N(CH3)2、またはCH2CH2CH2N(CH3)2であり、
RcはH、C(=O)NH−フェニルであり、フェニルは1つ以上のハロまたはハロアルキルで置換され、
RdはH、C1−C5−アルキル、OH、O−アルキル、OCH2CH2N(CH3)2、CH2CH2CH2N(CH3)2、SCH2CH2N(CH3)2、またはOCH2C(=O)O−アルキルであり、
ZはCH、C−O−(C1−C2−アルキル)、C−OCH2CH2N(CH3)2であり、および
XはCONH、SONH、SO2NH、NHC(=O)NH,またはNHCOであり、または薬剤的に許容可能な塩またはその水和物である。
WおよびZはそれぞれCHであり、Rbはエトキシであり、Rcは水素であり、およびRdは−OCH2CH2N(CH3)2またはOHであり、または
WはC−OCH2CH2N(CH3)2であり、ZはCHであり、Rbは水素であり、Rcは水素であり、Rdは水素であり、または
WおよびZはそれぞれCHであり、Rbはシクロペンチルオキシであり、Rcは水素であり、Rdは−OCH2CH2N(CH3)2であり、または
WおよびZはそれぞれCHであり、Rbは−OCH2CH2N(CH3)2であり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、およびRdは−OCH2CH2N(CH3)2であり、または
WはCHであり、ZはC−エトキシであり、Rbはエトキシであり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、およびRdは水素であり、
WおよびZはそれぞれCHであり、Rbは−CH2CH2CH2N(CH3)2であり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、およびRdは−CH2CH2CH2N(CH3)2または水素であり、または
WおよびZはそれぞれCHであり、Rbはエトキシであり、Rcは−C(O)NH−(3−CF3,4−Cl−フェニル)であり、およびRdは水素または−OCH2CH2N(CH3)2であり、または
WおよびZはそれぞれ窒素であり、Rbはエトキシであり、Rcは水素であり、およびRdは−OCH2CH2N(CH3)2であり、または
RbはH、O−(C1−C6−アルキル)、O−(C3−C8−シクロアルキル)、O−(C2−C6−アルケニル)、O−(C3−C8−ヘテロシクロアルキル)、N(R10)−(C1−C6−アルキル)、N(R10)−(C3−C8−シクロアルキル)、O−(C2−C6−アルキル)−N(R10)2、O−(C3−C8−シクロアルキル)−N(R10)2、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、O−(C3−C8−シクロアルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、O−アリール、またはO−ヘテロアリールであり、
RcはH、−(C1−C6−アルキル)、またはO−(C1−C6−アルキル)であり、
RdはH、OH、C1−C6−アルキル、O−(C3−C8−シクロアルキル)、O−(C3−C8−ヘテロシクロアルキル)、O−(C1−C6−アルキル)、−O−(C2−C6−アルケニル)、O−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−R3、O−(C1−C6−アルキル)−R3、N(R10)−(C1−C6−アルキル)−R3、−N(R10)−(C1−C6−アルキル)、−N(R10)−(C3−C8−シクロアルキル)、−N(R10)−(C3−C8−ヘテロシクロアルキル)、−N(R10)−(C2−C6−アルケニル)、N(R10)−(C2−C6−アルキル)−N(R10)2、−(C1−C6−アルキル)−N(R10)2、O−アリール、N−アリール、O−ヘテロアリール、またはN−ヘテロアリールであり、
WおよびZはCR1であり、
Xは−CO−、−CON(R10)−、−CON(R10)(CH2)n−、−(CH2)nN(R10)−、−C=N−であり、または
ArおよびXは一緒になって
R1はH、ハロゲン、O−(C1−C6−アルキル)、O−(C2−C6−アルキル)N(R10)2であり、
R2はハロゲンまたはハロアルキルであり、
R3はシクロアルキルアミノであり、N(R10)、OおよびSから選択されるヘテロ原子を含んでもよく、
R10は独立してH、−(C1−C4−アルキル)、−(C1−C4−ハロアルキル)、−(C3−C8−シクロアルキル)、−(C3−C8−ヘテロシクロアルキル)、アリールまたはヘテロアリールであり、およびnは1〜3の整数であり、または薬剤的に許容可能な塩である。
RbはO−(C1−C6)−アルキルまたはS−(C1−C6)−アルキルであり、
Rdは(C1−C6)−アルキルまたはO−(C1−C6)−アルキル−N(CH3)2であり、
Yはハロアルキル、C−CN、C−NO2、またはNであり、
WはCHまたはNであり、および
ZはCHまたはNであり、または薬剤的に許容可能な塩またはその水和物である。
R2はCNであり、および
RbはO−(C1−C6)−アルキルであり、または薬剤的に許容可能な塩またはその水和物である。
WおよびZは独立してCH、C−Cl、またはC−OEtであり、および
RcはH、エトキシル、またはメチルであり、または薬剤的に許容可能な塩またはその水和物である。
YはCH、C−ハロゲン、またはC−CNであり、
RbはH、O−(C1−C2−アルキル)、S−(C1−C2−アルキル)、O−シクロペンチル、OCH2CH2N(CH3)2、またはCH2CH2CH2N(CH3)2であり、
RcはH、C(=O)NH−フェニルであり、フェニルは1つ以上のハロまたはハロアルキルで置換され、
RdはH、C1−C5−アルキル、OH、O−アルキル、OCH2CH2N(CH3)2、CH2CH2CH2N(CH3)2、SCH2CH2N(CH3)2、またはOCH2C(=O)O−アルキルであり、
ZはCH、C−O−(C1−C2−アルキル)、C−OCH2CH2N(CH3)2であり、および
XはCONH、SONH、SO2NH、NHC(=O)NH,またはNHCOであり、または薬剤的に許容可能な塩またはその水和物である。
(a)試薬および条件:(i)NaOH/EtOH、還流6時間、(ii)[4−クロロ−3−(トリフルオロメチル)フェニル]メタンアミン、EDC、DCM、室温、一晩、(iii)ROH、PPh3、DIAD、THF、室温、24時間またはRX、K2CO3、DMF、80℃、24時間(X=ハロゲン)。
(c)試薬および条件:(i)NaBH4、BF3・OEt2、THF、60℃、24時間。
(d)試薬および条件:(i)4−クロロ−3−(トリフルオロメチル)アニリン、EDC、DCM、室温、24時間、(ii)2−クロロ−N、N−ジメチルエタンアミン、K2CO3、DMF、80℃、24時間。
(e)試薬および条件:(i)SOCl2、4−クロロ−3−(トリフルオロメチル)アニリン、DCM、還流、16時間、(ii)ROH、PPh3、DIAD、THF、室温、24時間またはRX、K2CO3、DMF、80℃、24時間(X=ハロゲン)。
(g)試薬および条件:(i)4−クロロ−3−(トリフルオロメチル)アニリン、AcOH、還流、2時間;(ii)RX、K2CO3、DMF、80℃、8時間(23については、X=ハロゲンであり、Rはエチルで、24時間、RXは2−クロロ−N、N−ジメチルエタンアミン)。
Claims (14)
- 下記式(I)の化合物又はその薬剤的に許容される塩。
(但し、式中、
nが、1であり、
Arは、下式:
で示され、
Raは、Xに対して、メタ位のCF3であり;
Rbは、O−(C2−C6−アルキル)であり;
Rcは、HまたはO−(C1−C6−アルキル)であり;
Rdは、O−(C2−C6−アルキル)−N(R10)2またはO−(C1−C6−アルキル)−R3であり;
WおよびZは、それぞれCHであり;
Xは、−CON(R10)−であり;
Yは、CR2であり;
R2は、ハロゲンであり;
R3は、ピペリジン−1−イル、モルフォリン−4−イル、またはチオモルフォリン−4−イルであり;
R10は、独立してHまたは−(C1−C4−アルキル)であり、
但し、
の時、Arは
ではなく、式中、
WおよびZは、それぞれCHであり、Rbは、エトキシであり、Rcは、水素であり、Rdは、−OCH2CH2N(CH3)2である。) - 請求項1に記載の化合物であって、式中
Arは
であり;
Raは、Xに対して、メタ位のCF3であり;
Rbは、O−(C2−C4−アルキル)であり;
Rcは、Hであり;
Rdは、O−(C2−C4−アルキル)−N(R10)2またはO−(C1−C4−アルキル)−R3であり;
WおよびZは、それぞれCHであり;
Xは、−CON(R10)−であり;
Yは、CR2であり;
R2は、ハロゲンであり;
R3は、ピペリジン−1−イル、モルフォリン−4−イル、またはチオモルフォリン−4−イルであり;
R10は、独立してHまたは−(C1−C2−アルキル)である化合物。 - 請求項1に記載の化合物であって、式中
Arは
であり;
Raは、Xに対して、メタ位のCF3であり;
Rbは、O−(C2−C4−アルキル)であり;
Rcは、Hであり;
Rdは、O−(C2−C4−アルキル)−N(R10)2であり;
WおよびZは、それぞれCHであり;
Xは、−CON(H)−であり;
Yは、CR2であり;
R2は、ハロゲンであり;
R10は、独立してHまたは−(C1−C2−アルキル)である化合物。 - 請求項1〜3のいずれかに記載の化合物であって、ここで、化合物は
であり、
式中、Rdは、−O−(C2−C6−アルキル)−N(R10)2または−O−(C1−C6−アルキル)−R3であり、ここで、R3は、ピペリジン−1−イル、モルフォリン−4−イル、またはチオモルフォリン−4−イルであり、R10は、独立して、Hまたは−(C1−C2−アルキル)である化合物。 - 請求項1〜3のいずれかに記載の化合物であって、ここで、化合物は
であり、式中、Rbは、−O−(C2−C6−アルキル)である化合物。 - 請求項1〜3のいずれかに記載の化合物であって、ここで、化合物は
であり、式中、R10は、−(C1−C4−アルキル)である化合物。 - 請求項1〜3のいずれかに記載の化合物であって、ここで、化合物は、
であり、Raは、Xに対して、メタ位のCF3であり、Yは、CR2であり、R2は、ハロゲンである化合物。 - 以下の化合物からなる群から選択される請求項1に記載の化合物。
- 以下の式:
の化合物またはその薬剤的に許容される塩である、請求項1に記載の化合物。 - 以下の式:
の化合物またはその薬剤的に許容される塩である、請求項1に記載の化合物。 - 以下の式:
の化合物またはその薬剤的に許容される塩である、請求項1に記載の化合物。 - 以下の式:
の化合物またはその薬剤的に許容される塩である、請求項1に記載の化合物。 - 以下の式:
の化合物またはその薬剤的に許容される塩である、請求項1に記載の化合物。 - 以下の式:
の化合物またはその薬剤的に許容される塩。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201061426033P | 2010-12-22 | 2010-12-22 | |
US61/426,033 | 2010-12-22 | ||
US201161539697P | 2011-09-27 | 2011-09-27 | |
US61/539,697 | 2011-09-27 | ||
US201161541706P | 2011-09-30 | 2011-09-30 | |
US61/541,706 | 2011-09-30 | ||
PCT/US2011/066851 WO2012088420A1 (en) | 2010-12-22 | 2011-12-22 | Histone acetyltransferase modulators and usese thereof |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017142246A Division JP6629797B2 (ja) | 2010-12-22 | 2017-07-21 | ヒストンアセチル基転移酵素モジュレーターおよびその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014501763A JP2014501763A (ja) | 2014-01-23 |
JP2014501763A5 JP2014501763A5 (ja) | 2015-02-05 |
JP6616057B2 true JP6616057B2 (ja) | 2019-12-04 |
Family
ID=46314479
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013546423A Active JP6616057B2 (ja) | 2010-12-22 | 2011-12-22 | ヒストンアセチル基転移酵素モジュレーターおよびその使用 |
JP2017142246A Active JP6629797B2 (ja) | 2010-12-22 | 2017-07-21 | ヒストンアセチル基転移酵素モジュレーターおよびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017142246A Active JP6629797B2 (ja) | 2010-12-22 | 2017-07-21 | ヒストンアセチル基転移酵素モジュレーターおよびその使用 |
Country Status (7)
Country | Link |
---|---|
US (2) | US9969677B2 (ja) |
EP (2) | EP2654428B1 (ja) |
JP (2) | JP6616057B2 (ja) |
CN (2) | CN106432137B (ja) |
CA (1) | CA2822621C (ja) |
ES (1) | ES2820863T3 (ja) |
WO (1) | WO2012088420A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034647B2 (en) | 2009-12-10 | 2021-06-15 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2654428B1 (en) * | 2010-12-22 | 2018-02-14 | The Trustees of Columbia University in the City of New York | Histone acetyltransferase modulators and usese thereof |
WO2012149106A1 (en) | 2011-04-29 | 2012-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
JP6175078B2 (ja) | 2012-02-01 | 2017-08-02 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | 新規のシステインプロテアーゼ阻害剤及びその使用 |
EP2970124B1 (en) | 2013-03-14 | 2019-05-22 | The Board of Trustees of the Leland Stanford Junior University | Mitochondrial aldehyde dehydrogenase-2 modulators and methods of use thereof |
EP2968322B1 (en) | 2013-03-15 | 2018-12-26 | The Trustees of Columbia University in the City of New York | Map kinase modulators and uses thereof |
US10899756B2 (en) | 2013-07-17 | 2021-01-26 | The Trustees Of Columbia University In The City Of New York | Phosphodiesterase inhibitors and uses thereof |
US20170182054A1 (en) | 2014-03-31 | 2017-06-29 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
MX2017000135A (es) | 2014-06-27 | 2017-04-10 | Nogra Pharma Ltd | Moduladores del receptor arilo y metodos para elaborar y usar los mismos. |
KR101755530B1 (ko) | 2016-02-02 | 2017-07-10 | 한남대학교 산학협력단 | 퇴행성 신경계 질환 진단용 마커 및 이를 이용한 진단방법 |
JP2019527226A (ja) | 2016-07-20 | 2019-09-26 | ザ トラスティース オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | ヒストンアセチルトランスフェラーゼ活性化剤及び組成物並びにそれらの使用 |
CN108358894B (zh) * | 2018-04-26 | 2021-05-07 | 四川大学 | 一种抑制组蛋白乙酰转移酶的化合物及其制备方法与应用 |
CN108957004B (zh) * | 2018-07-09 | 2021-10-19 | 东南大学 | 检测H3K9me2和H3K36me3表达量的试剂在制备胃癌预后评估试剂盒中的应用 |
CA3129246A1 (en) * | 2019-02-08 | 2020-08-13 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase modulators and compositions and uses thereof |
JP2022520945A (ja) * | 2019-02-08 | 2022-04-04 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ヒストンアセチルトランスフェラーゼ(hat)レギュレーターおよびその使用 |
CN111249276B (zh) * | 2020-03-05 | 2021-07-13 | 南京巴傲得生物科技有限公司 | 吲哚布洛芬制备cbp溴区抑制试剂的用途 |
Family Cites Families (79)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB728098A (en) | 1952-03-05 | 1955-04-13 | Geigy Ag J R | Improvements relating to salicylanilides and their use |
BE639158A (ja) | 1961-12-05 | |||
US4118332A (en) | 1965-10-22 | 1978-10-03 | Colgate-Palmolive Company | Synergistic antibacterial composition containing mixtures of certain halogenated diphenyl ethers and trichlorocarbanilides |
US3497508A (en) * | 1966-09-22 | 1970-02-24 | Sandoz Ag | Alpha-(2-(morpholinomethyl)phenyl) benzyl alcohols |
DE1642224B2 (de) | 1967-04-28 | 1976-04-29 | Basf Ag, 6700 Ludwigshafen | Verwendung von substituierten benzoesaeureaniliden zur bekaempfung von pilzen aus der klasse der basidiomyceten |
US3591684A (en) | 1968-05-29 | 1971-07-06 | Monsanto Co | Controlling southern armyworm with 3-iodo-3',4',5-trichlorosalicylanilide |
US3671630A (en) | 1970-08-17 | 1972-06-20 | Lever Brothers Ltd | Halogenated phenolic germicidal compositions containing terpene color stabilizers |
US4088770A (en) | 1971-05-04 | 1978-05-09 | Eli Lilly And Company | Substituted 2-anilinobenzoxazoles used as immunosuppressive agents |
JPS5541202Y2 (ja) | 1971-10-07 | 1980-09-26 | ||
CH609558A5 (en) | 1973-09-18 | 1979-03-15 | Givaudan & Cie Sa | Antibacterial composition |
JPS5920686B2 (ja) * | 1975-01-11 | 1984-05-15 | 日立電線株式会社 | 難燃性樹脂の製造方法 |
JPS55129256A (en) | 1979-02-28 | 1980-10-06 | Isao Ozawa | Antifungal compound |
JPS5687501A (en) | 1979-12-19 | 1981-07-16 | Nissan Chem Ind Ltd | Agricultural and horticultural germicide containing salicylic acid anilide as active constituent |
JPS5687502A (en) | 1979-12-19 | 1981-07-16 | Nissan Chem Ind Ltd | Agricultural and horticultural germicide of salicylic acid anilide |
ATE168416T1 (de) | 1989-10-05 | 1998-08-15 | Optein Inc | Zellfreie synthese und isolierung von genen und polypeptiden |
US5747334A (en) | 1990-02-15 | 1998-05-05 | The University Of North Carolina At Chapel Hill | Random peptide library |
GB9015658D0 (en) | 1990-07-17 | 1990-09-05 | Shell Int Research | Herbicidal compounds |
IE71647B1 (en) * | 1991-01-28 | 1997-02-26 | Rhone Poulenc Rorer Ltd | Benzamide derivatives |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
US5430062A (en) * | 1992-05-21 | 1995-07-04 | Research Corporation Technologies, Inc. | Stilbene derivatives as anticancer agents |
US5565325A (en) | 1992-10-30 | 1996-10-15 | Bristol-Myers Squibb Company | Iterative methods for screening peptide libraries |
EP0740791A4 (en) | 1994-01-05 | 2000-04-05 | Arqule Inc | SYSTEMATIC MODULAR PRODUCTION OF AMINIMID AND OXAZOLONE-BASED MOLECULES WITH SELECTED PROPERTIES |
DE4428380A1 (de) * | 1994-08-11 | 1996-02-15 | Bayer Ag | 4-Trifluormethylbenzamide |
US5712171A (en) | 1995-01-20 | 1998-01-27 | Arqule, Inc. | Method of generating a plurality of chemical compounds in a spatially arranged array |
US5814646A (en) | 1995-03-02 | 1998-09-29 | Eli Lilly And Company | Inhibitors of amyloid beta-protein production |
AU2962297A (en) * | 1996-05-24 | 1998-01-05 | Neurosearch A/S | Phenyl derivatives useful as blockers of chloride channels |
WO1998037068A1 (en) | 1997-02-21 | 1998-08-27 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
AR013269A1 (es) | 1997-08-04 | 2000-12-13 | Scras | Producto que contiene por lo menos un rna de doble filamento combinado con por lo menos un agente anti-viral, para la utilizacion terapeutica en eltratamiento de una enfermedad viral, en especial de la hepatitis viral |
US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
EP1076641A1 (en) | 1998-04-29 | 2001-02-21 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
HUP0102782A3 (en) | 1998-06-19 | 2002-12-28 | Smithkline Beecham Corp | Salycilanilide as inhibitors of transcription factor nf-kb |
GB9827152D0 (en) | 1998-07-03 | 1999-02-03 | Devgen Nv | Characterisation of gene function using double stranded rna inhibition |
WO2000044914A1 (en) | 1999-01-28 | 2000-08-03 | Medical College Of Georgia Research Institute, Inc. | Composition and method for in vivo and in vitro attenuation of gene expression using double stranded rna |
DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
EP2308833A3 (en) | 1999-04-15 | 2011-09-28 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
TNSN00139A1 (fr) | 1999-06-25 | 2005-11-10 | Inst For Pharm Discovery Inc | Acides phenoxyacetiques substitues |
JP2003516124A (ja) | 1999-10-15 | 2003-05-13 | ユニバーシティー オブ マサチューセッツ | 標的とした遺伝的干渉の手段としてのrna干渉経路遺伝子 |
GB9927444D0 (en) | 1999-11-19 | 2000-01-19 | Cancer Res Campaign Tech | Inhibiting gene expression |
US6369030B1 (en) * | 1999-11-29 | 2002-04-09 | The Rockfeller University | Inhibitors of histone acetyltransferases (HATs) and uses thereof |
US20020042394A1 (en) | 2000-05-31 | 2002-04-11 | Hogenkamp Henricus P.C. | Cobalamin compounds useful as antibiotic agents and as imaging agents |
JP4083422B2 (ja) | 2000-12-22 | 2008-04-30 | 石原産業株式会社 | アニリン誘導体またはその塩ならびにそれらを含有するサイトカイン産生抑制剤 |
US20050227915A1 (en) | 2001-05-02 | 2005-10-13 | Steffan Joan S | Methods and reagents for treating neurodegenerative diseases and motor deficit disorders |
CA2487900A1 (en) * | 2002-06-05 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Immunity-related protein kinase inhibitors |
EA010835B1 (ru) * | 2002-06-10 | 2008-12-30 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. | Лекарственное средство для лечения рака |
WO2003103657A1 (ja) * | 2002-06-11 | 2003-12-18 | 株式会社医薬分子設計研究所 | 神経変性疾患治療剤 |
WO2004006906A2 (en) | 2002-07-15 | 2004-01-22 | Combinatorx, Incorporated | Methods for the treatment of neoplasms |
CN1681487A (zh) | 2002-07-15 | 2005-10-12 | 美瑞德生物工程公司 | 化合物、组合物及其使用方法 |
WO2004041256A2 (en) | 2002-11-08 | 2004-05-21 | Novo Nordisk A/S | Safe chemical uncouplers for the treatment of obesity |
AU2003289222A1 (en) | 2002-12-06 | 2004-06-30 | Toray Industries, Inc. | Benzomorpholine derivatives |
WO2004053140A2 (en) | 2002-12-12 | 2004-06-24 | Jawaharlal Nehru Centre For Advanced Scientific Research | Modulators (inhibitors/activators) of histone acetyltransferases |
US7332629B2 (en) | 2002-12-12 | 2008-02-19 | Jawaharlal Nehru Centre For Advanced Scientific Research | Modulators (inhibitors/activators) of histone acetyltransferases |
WO2004063715A2 (en) | 2003-01-10 | 2004-07-29 | The Trustees Of Columbia University In The City Of New York | Methods of using crystal structure of carboxyltransferase domain of acetyl-coa carboxylase, modulators thereof, and computer methods |
ATE482747T1 (de) | 2003-04-11 | 2010-10-15 | High Point Pharmaceuticals Llc | Neue amide derivate und deren pharmazeutische verwendungen |
KR20060054308A (ko) | 2003-07-16 | 2006-05-22 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 피부 색소침착의 치료제 |
EP1724268A4 (en) * | 2004-02-20 | 2010-04-21 | Kirin Pharma Kk | COMPOUND HAVING TGF-BETA INHIBITING ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME |
US7638553B2 (en) | 2004-06-14 | 2009-12-29 | Hoffmann-La Roche Inc. | Hydroxamates, their manufacture and use as pharmaceutical agents |
US20060045953A1 (en) | 2004-08-06 | 2006-03-02 | Catherine Tachdjian | Aromatic amides and ureas and their uses as sweet and/or umami flavor modifiers, tastants and taste enhancers |
WO2006132583A1 (en) | 2005-06-07 | 2006-12-14 | Innate Pharmaceuticals Ab | Method and means for preventing and inhibiting respiratory disease, atherosclerosis and osteoporosis caused by chlamydia pneumoniae infection |
WO2007008541A2 (en) * | 2005-07-08 | 2007-01-18 | Kalypsys, Inc. | Cellular cholesterol absorption modifiers |
US8158828B2 (en) | 2005-11-28 | 2012-04-17 | Gtx, Inc. | Nuclear receptor binding agents |
EP1991215A1 (en) * | 2006-03-09 | 2008-11-19 | Cenix Bioscience GmbH | Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases |
US20100144885A1 (en) | 2006-09-29 | 2010-06-10 | The Board Of Trustees Of The University Of Illinois | Histone acetyl transferase activators and histone deacetylase inhibitors in the treatment of alcoholism |
US8088951B2 (en) | 2006-11-30 | 2012-01-03 | Massachusetts Institute Of Technology | Epigenetic mechanisms re-establish access to long-term memory after neuronal loss |
CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
GB0713686D0 (en) * | 2007-07-13 | 2007-08-22 | Addex Pharmaceuticals Sa | New compounds 2 |
BRPI0815038A2 (pt) | 2007-08-02 | 2015-03-17 | Hoffmann La Roche | Uso de derivados de benzamida para o tratamento de transtornos do cns |
EP2205225A4 (en) | 2007-10-03 | 2013-09-18 | Jncasr Bangalore | INTRINSIC FLUORESCENT CARBON NANOTONES AND METHOD THEREFOR |
TWI447393B (zh) | 2007-10-26 | 2014-08-01 | Toppan Printing Co Ltd | 反應晶片及其製造方法 |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
FR2926463B1 (fr) | 2008-01-22 | 2010-08-13 | Centre Nat Rech Scient | Utilisation d'inhibiteurs d'aminopeptidase ou de composes azaindole pour la prevention ou le traitement de metastases cancereuses d'origine epitheliale |
FR2928370B1 (fr) | 2008-03-07 | 2017-07-14 | Catalys | Preparation de composes hydroquinone-amide a proprietes anti-oxydantes |
RU2370484C1 (ru) | 2008-04-02 | 2009-10-20 | Государственное образовательное учреждение высшего профессионального образования САНКТ-ПЕТЕРБУРГСКАЯ ГОСУДАРСТВЕННАЯ ХИМИКО-ФАРМАЦЕВТИЧЕСКАЯ АКАДЕМИЯ (ГОУ ВПО СПХФА Росздрава) | Антигельминтное средство на основе n-(3-хлор-4-метилфенил)-3,5-дибромсалициламида |
US20100168084A1 (en) | 2008-05-08 | 2010-07-01 | Huber L Julie | Therapeutic compounds and related methods of use |
US20110081403A1 (en) | 2009-10-01 | 2011-04-07 | Gradalis, Inc. | Histone octamers for increased nucleic acid transfer |
CN101698651A (zh) | 2009-10-23 | 2010-04-28 | 南京大学中国医药城研发中心 | 水杨酰苯胺类衍生物及其制法与用途 |
JP6093180B2 (ja) * | 2009-12-10 | 2017-03-08 | トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | ヒストンアセチルトランスフェラーゼ活性化剤及びその使用 |
US10640457B2 (en) * | 2009-12-10 | 2020-05-05 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
EP2654428B1 (en) * | 2010-12-22 | 2018-02-14 | The Trustees of Columbia University in the City of New York | Histone acetyltransferase modulators and usese thereof |
JP5541202B2 (ja) | 2011-03-16 | 2014-07-09 | コニカミノルタ株式会社 | スプレッドシートデータ生成装置およびプログラム |
-
2011
- 2011-12-22 EP EP11850544.5A patent/EP2654428B1/en active Active
- 2011-12-22 US US13/996,483 patent/US9969677B2/en active Active
- 2011-12-22 CN CN201610811111.XA patent/CN106432137B/zh not_active Expired - Fee Related
- 2011-12-22 WO PCT/US2011/066851 patent/WO2012088420A1/en active Application Filing
- 2011-12-22 EP EP17207865.1A patent/EP3323813B1/en active Active
- 2011-12-22 CA CA2822621A patent/CA2822621C/en active Active
- 2011-12-22 JP JP2013546423A patent/JP6616057B2/ja active Active
- 2011-12-22 ES ES17207865T patent/ES2820863T3/es active Active
- 2011-12-22 CN CN201180066968.9A patent/CN103347392B/zh not_active Expired - Fee Related
-
2017
- 2017-07-21 JP JP2017142246A patent/JP6629797B2/ja active Active
-
2018
- 2018-05-01 US US15/968,524 patent/US20180244603A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11034647B2 (en) | 2009-12-10 | 2021-06-15 | The Trustees Of Columbia University In The City Of New York | Histone acetyltransferase activators and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN103347392B (zh) | 2016-10-12 |
JP2017193578A (ja) | 2017-10-26 |
EP3323813B1 (en) | 2020-08-26 |
EP2654428A4 (en) | 2014-08-27 |
ES2820863T3 (es) | 2021-04-22 |
CN103347392A (zh) | 2013-10-09 |
EP3323813A1 (en) | 2018-05-23 |
CA2822621A1 (en) | 2012-06-28 |
JP6629797B2 (ja) | 2020-01-15 |
EP2654428B1 (en) | 2018-02-14 |
CN106432137B (zh) | 2020-11-06 |
WO2012088420A1 (en) | 2012-06-28 |
US20180244603A1 (en) | 2018-08-30 |
US9969677B2 (en) | 2018-05-15 |
CA2822621C (en) | 2020-12-15 |
EP2654428A1 (en) | 2013-10-30 |
JP2014501763A (ja) | 2014-01-23 |
US20170121276A1 (en) | 2017-05-04 |
CN106432137A (zh) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6616057B2 (ja) | ヒストンアセチル基転移酵素モジュレーターおよびその使用 | |
US11034647B2 (en) | Histone acetyltransferase activators and uses thereof | |
US20230165813A1 (en) | Histone acetyltransferase activators and compositions and uses thereof | |
JP6093180B2 (ja) | ヒストンアセチルトランスフェラーゼ活性化剤及びその使用 | |
US11191768B2 (en) | Histone acetyltransferase activators and uses thereof | |
Kamiński et al. | New hybrid molecules with anticonvulsant and antinociceptive activity derived from 3-methyl-or 3, 3-dimethyl-1-[1-oxo-1-(4-phenylpiperazin-1-yl) propan-2-yl] pyrrolidine-2, 5-diones | |
JP2011518188A (ja) | リソソーム調節のための化合物および使用方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141210 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20141210 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150827 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150916 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20151211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160316 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160704 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161003 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20161205 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170104 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170321 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170721 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170911 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20171020 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180905 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190412 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190604 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190716 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190905 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191107 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6616057 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |